Omrix biopharmaceuticals, Inc. is a company.
Key people at Omrix biopharmaceuticals, Inc..
Omrix biopharmaceuticals, Inc. was founded by Robert Taub (Founder and CEO).
Omrix biopharmaceuticals, Inc. was founded by Robert Taub (Founder and CEO).
Key people at Omrix biopharmaceuticals, Inc..
Omrix Biopharmaceuticals Ltd. is a biotechnology company specializing in the development and manufacturing of life-saving medical products derived from human plasma, particularly biological adhesives for biosurgery to control massive internal bleeding.[1][4] Founded in 1995 and acquired by Johnson & Johnson, it serves surgeons and patients worldwide by addressing unmet needs in hemostasis (stopping bleeding) through innovative products like Evicel® (launched earlier, awarded in 2012) and EVARREST® (launched 2015), which have set benchmarks in surgical innovation.[1] With 100-249 employees and estimated revenue of $25M-$50M, Omrix operates as part of Johnson & Johnson MedTech, focusing on proprietary protein purification and manufacturing to improve patient outcomes in critical procedures.[2][5]
Omrix Biopharmaceuticals was established in 1995 in Israel as an independent biotech firm, leveraging expertise in human plasma-derived products.[1] It gained early traction through pioneering biological adhesives for biosurgery, with its first major product, Evicel®, earning Johnson & Johnson's top R&D award in 2012 for revolutionizing internal bleeding control.[1] The company's pivotal acquisition by Johnson & Johnson integrated it into a global powerhouse, enabling launches like EVARREST® in 2015, which quickly became a flagship in the U.S. medical community for its efficacy in hemorrhage management.[1] This evolution from a startup innovator to a key J&J subsidiary underscores its commitment to plasma-based therapies amid growing demand for safer surgical solutions.[2]
Omrix rides the wave of advancing biosurgery and plasma-derived biologics, capitalizing on trends in minimally invasive procedures and demand for fibrin sealants amid rising surgical volumes globally.[1][2] Its timing aligns with post-2010s growth in hemostatic agents, where plasma-based products address limitations of synthetic alternatives in complex surgeries like trauma and transplants.[1] Market forces favoring Omrix include aging populations driving surgical needs, regulatory approvals for innovative adhesives, and J&J's distribution muscle amplifying reach.[1][4] As part of J&J MedTech, it influences the ecosystem by setting efficacy standards, fostering R&D in human-derived therapies, and enabling safer operations that reduce complications and healthcare costs.[2]
Omrix is poised for sustained growth within J&J MedTech, with potential expansions in plasma-based hemostats for emerging applications like robotic surgery and regenerative medicine. Trends like personalized biologics and AI-optimized manufacturing will shape its trajectory, enhancing product precision and global adoption. Its influence may evolve by pioneering next-gen adhesives, solidifying J&J's dominance in biosurgery while continuing to transform patient care from a plasma-derived foundation.[1][2]
